UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------------------------------------------------------------------
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 27, 2004
--------------------------
PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada 0-9410 90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of (Commission (I.R.S. Employer
Incorporation or Organization) File Number) Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: 865/769-4011
--------------------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.1. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) (UIR:FRK2541) announced today,
October 27, 2004, that one of the largest national distributors of
pharmaceutical products has accepted delivery of the company's Pure-ific
antibacterial hand spray for sale in 504 stores in the western region of the
United States.
"We are particularly happy to get this campaign started right now, at the onset
of cold and flu season, and we expect to build upon this beginning and extend
sales into other regions of the country," said Pure-fic President Timothy C.
Scott, Ph. D. "This first shipment of product is destined for sales in the
states of California, Utah, Arizona, and Washington."
Pure-ific, which comes in a 1-ounce can, immediately kills up to 99.9 percent of
germs on skin and prevents re-growth for up to six hours. Packaged as a
quick-drying spray, Pure-ific is useful for mothers, travelers, and anyone else
concerned about the spread of germs. Unlike gel sanitizers, Pure-ific
Antibacterial Hand Spray leaves no sticky residue and is appropriate both for
hands and for hard surfaces, such as toilet seats.
Provectus Pharmaceuticals Inc. plans to license and sell products in three
sectors of the health-care industry: 1) prescription medications and treatments,
2) medical devices, and 3) over-the-counter (OTC) pharmaceuticals, such as
Pure-ific. Prescription drug products and devices address several forms of
difficult-to-treat cancers as well as diseases of the skin. OTC products address
complementary markets, primarily those involving skin care and comfort.
The company's offices and laboratory are located at 7327 Oak Ridge Highway,
Suite A Knoxville, TN 37931; telephone: 865/769-4011. For more information,
contact the company at info@pvct.com or visit the corporate Web site:
www.pvct.com.
Forward-Looking Statements
This information and others statements issued or made from time to time by the
company or its representatives contain statements that may constitute
forward-looking statements. Those statements include statements regarding the
intent, belief or current expectations of the company and members of its
management teams as well as the assumptions on which the statements are based.
Prospective investors are cautioned that such forward-looking statements are not
guarantees of future performance and involve risks and uncertainties,and that
actual results may differ materially from those contemplated by such
forward-looking statements.
___________________________
Corporate Contact: Provectus Pharmaceuticals, Craig Dees, CEO (865) 769-4011
Media Contacts: Emily Carlton or George Pappas, HKA, Inc., 714 426-0444 (PDT),
Emily@hkamarcom.com
Source: Provectus Pharmaceuticals Inc.
Terms of the Agreement
The Supply Agreement is a nonexclusive agreement whereby Provectus agrees
to sell products to AmerisourceBergen as an authorized distributor of record.
The Agreement continues until June 1, 2005 and thereafter automatically renews
for subsequent terms of one year.
Item 9.01 Financial Statements and Exhibits
(a) Exhibits
99.1 Supply Agreement between AmerisourceBergen Drug Corporation and
Provectus Pharmaceuticals, Inc. dated June 1, 2004.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Provectus Pharmaceuticals, Inc.
Dated: November 10, 2004 By:/s/ H. Craig Dees
------------------------------------------
H. Craig Dees
Chief Executive Officer